Piper Jaffray Starts BridgeBio Pharma (BBIO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Piper Jaffray Starts BridgeBio Pharma (BBIO) at Overweight
July 22, 2019 6:17 AM EDT
SVB Leerink initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating and a price target of $34.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
...
More
July 22, 2019 4:25 AM EDT
JPMorgan initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Overweight rating and a price target of $38.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
...
More
July 22, 2019 3:58 AM EDT
Jefferies analyst Eun Yang initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Buy rating and a price target of $38.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
...
More
July 22, 2019 2:28 AM EDT
Goldman Sachs analyst Paul Choi initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Buy rating and a price target of $42.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
...
More
July 22, 2019 1:57 AM EDT
BMO Capital analyst George Farmer initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating and a price target of $49.00.
The analyst comments "We believe BridgeBio's platform of 16 products in preclinical and clinical development offers a compelling opportunity for investors looking for prudent... More
